COMMISSION TRIALS OF THE MANUFACTURING TECHNOLOGY, AND PHYSICAL AND IMMUNOBIOLOGICAL PROPERTIES, OF A NOVEL LIVE MODIFIED COLD-ADAPTED VIRAL VACCINE AGAINST EQUINE INFLUENZA
Main Article Content
Authors
K.K. Tabynov
The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambulskaya oblast, 080409, Kazakhstan
N.N. Assanzhanova
The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambulskaya oblast, 080409, Kazakhstan
Sh.Zh. Ryskeldinova
The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambulskaya oblast, 080409, Kazakhstan
Y.M. Kozhamkulov
The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambulskaya oblast, 080409, Kazakhstan
D.A. Inkarbekov
The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambulskaya oblast, 080409, Kazakhstan
Zh. Kydyrbayev
The Research Institute for Biological Safety Problems, Gvardeiskiy, Kordaiskiy rayon, Zhambulskaya oblast, 080409, Kazakhstan
Abstract
We developed a novel live modified viral vaccine for specific prophylaxis of equine influenza virus subtype H3N8, based on the reassortant cold-adapted strain, A/HK/Otar/6:2/2010. Previously we performed all stages of vaccine development, from a battery of laboratory studies, to isolating the vaccine strain, up to evaluation of vaccine safety and effectiveness in horses. The next important step is to summarise the laboratory studies and to confirm compliance of the properties of the developed vaccine with the requirements (specification) of the normative and technical documentation (NTD) draft for vaccine preparation. The results of this study will determine the potential for use of the vaccine in compliance with the NTD for approval by the authorized state body in the field of veterinary medicine.
The process of manufacturing and quality control of the finished vaccine was carried out in accordance with an approved program, which was based on the draft NTD for the vaccine. The studies demonstrated that a laboratory series of vaccine (13,400 vials or 134,000 doses), prepared according to the developed methodology, met the requirements of the draft NTD completely with regards to quality parameters including appearance, the presence of impurities, vacuum, solubility, pH, mass fraction of humidity, sterility, infectious activity, safety and immunogenicity. The vaccine, therefore, withstood the commission trials. The results of these commission trials of a novel live modified cold-adapted viral vaccine against equine influenza will subsequently be presented for agreement and approval, according to the draft NTD.Keywords: equine influenza, vaccine, cold-adapted strain, normative and technical documentation, physical properties, safety, immunogenicity, commission trials.
Keywords
equine influenza, vaccine, cold-adapted strain, normative and technical documentation, physical properties, safety, immunogenicity, commission trials
Article Details
References
Sidorchuk A.A., Bessarabov B.F., Voronin E.S. Infekcionnye bolezni zhivotnyh. M., Kolos, 2007, 671 p.
Paillot R., Hannant D., Kydd J.H., Daly J.M. Vaccination against equine influenza: Quid novi? Vaccine, 2006, vol. 24, no. 19, pp. 4047-4061. PMID: 16545507. doi:10.1016/j.vaccine.2006.02.030.
Wilson W.D. Equine influenza. Vet Clin North Am Equine Pract, 1993, vol. 9, no. 2, pp. 257-282. PMID: 8358645.
Chambers T.M., Holland R.E., Tudor L.R., Townsend H.G.G. et al. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet J, 2001, vol. 33, no. 7, pp. 630-636. PMID: 11770982. DOI: 10.2746/042516401776249291.
Townsend H.G., Penner S.J., Watts T.C. et al. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J, 2001, vol. 33, no. 7, pp. 637-643. PMID: 11770983. DOI: 10.2746/042516401776249354.
Tabynov K., Kydyrbayev Zh., Ryskeldinova Sh., Assanzhanova N., Kozhamkulov Y., Inkarbekov D., Sansyzbay A. The safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine. Aust Vet J, 2014, vol. 92, no. 11, pp. 450-457. PMID: 25348146. DOI: 10.1111/avj.12248.
Tabynov K., Kydyrbayev Zh., Ryskeldinova Sh., Assanzhanova N., Sansyzbay A. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza. Vaccine, 2014, vol. 32, no. 25, pp. 2965-2971. PMID: 24726250. DOI:10.1016/j.vaccine.2014.03.095.
Chervyakova O.V., Strochkov V.M., Tailakova E.T., Sultankulova K.T. et al. Recombinant Strain A/HK/Otar/6:2/2010 (H3N8) for Development of a Live Intranasal Equine Influenza Vaccine. Journal of Equine Veterinary Science, 2014, vol. 34, no. 6, pp. 749-758. DOI:10.1016/j.jevs.2014.01.003.
Asanzhanova N.N., Tabynov K.K., Kydyrbaev Zh.K., Ryskel'dinova Sh.Zh. Sravnitel'noe izuchenie reproduktivnyh svojstv klonov reassortantnogo holodoadaptirovannogo shtamma A/HK/Otar/6:2/2010 (H3N8) virusa grippa na kurinyh jembrionah // Materialy pervoj nauchno-prakticheskoj konferencii molodyh uchenyh «Aktual'nye problemy i perspektivy biologicheskoj bezopasnosti», posvjashhennoj ko dnju obrazovanija Nauchno-issledovatel'skogo instituta problem biologicheskoj bezopasnosti. Gvardejskij, 2012, pp. 21-29.
Asanzhanova N.N., Tabynov K.K., Kydyrbaev Zh.K., Ryskel'dinova Sh.Zh., Kozhamkulov E.M., Inkarbekov D.A. Izuchenie bezvrednosti i immunogennosti klonov reassortantnogo shtamma A/HK/Otar/6:2/2010 (H3N8) virusa grippa na modeli laboratornyh zhivotnyh. Biotehnologija. Teorija i praktika, 2012, no. 1, pp. 69-76.
Tabynov K.K., Kydyrbaev Zh.K., Kozhamkulov E.M., Inkarbekov D.A., Asanzhanova N.N., Ryskel'dinova Sh.Zh. Opredelenie inficirujushhej dozy jepizooticheskogo shtamma A/loshad'/Otar/764/07 (H3N8) virusa grippa dlja loshadej. Biotehnologija. Teorija i praktika, 2011, no. 4, pp. 110-114.
Tabynov K.K., Kydyrbaev Zh.K., Sansyzbaj A.R., Ryskel'dinova Sh.Zh., Asanzhanova N.N., Kozhamkulov E.M., Inkarbekov D.A. Jeksperimental'noe izuchenie bezvrednosti i immunogennosti holodoadaptirovannogo reassortantnogo shtamma A/HK/Otar/6:2/2010 virusa grippa na loshadjah. Aktual'nye voprosy veterinarnoj biologii, 2012, no. 3, pp. 87-99.
Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg, 1938, vol. 27, pp. 493-497.
OIE. Terrestrial manual equine influenza. 2008, chapter 2.5.7, pp. 877-881.
Heldens G.M., Pouwels H.G.W., Derks C.G.G., Van de Zande S.M.A., Hoei-jmakers M.J.H. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap. Vaccine, 2009, vol. 27, no. 40, pp. 5530-5537. PMID:19607950. DOI:10.1016/j.vaccine.2009.06.085.
Kydyrmanov A.I., Kumekbaeva Zh.Zh., Karamendin K.O. Izoljacija virusa grippa A (H3N8) ot loshadej v Kazahstane v 2007 g. Veterinarija, 2009, no. 5, pp. 52-54.
OIE Expert Surveillance Panel on Equine Influenza Vaccine Composition, OIE Headquarters. URL 4 March 2013.
Soboll G., Nelson K.M., Leuthner E.S., Clark R.J. et al. Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. Vaccine, 2003, vol. 21, no. 21-22, pp. 3081-3092. PMID:12798652. DOI:10.1016/S0264-410X(03)00161-0.
Potapchuk M.V., Repko I.A., Sergeeva M.V., Korotkov A.V. et al. Harakteristika reassortantnyh shtammov virusa grippa na osnove novogo donora A/HongKong/1/68/162/35 (H3N2). Voprosy virusologii, 2012, vol. 57, no. 6, pp. 42-46. PMID: 23477254.